Get the Stockscreener App
2.18
0.68%
-0.015
Xenetic Biosciences Inc stock is traded at $2.18, with a volume of 1,524.
It is down -0.68% in the last 24 hours and down -13.83% over the past month.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
See More
Previous Close:
$2.195
Open:
$2.2
24h Volume:
1,524
Relative Volume:
0.00
Market Cap:
$5.02M
Revenue:
$2.54M
Net Income/Loss:
$-4.13M
P/E Ratio:
-0.7927
EPS:
-2.75
Net Cash Flow:
$-4.11M
1W Performance:
+4.81%
1M Performance:
-13.83%
6M Performance:
-41.08%
1Y Performance:
-49.54%
1-Day Range:
$2.19
$2.20
1-Week Range:
$2.0937
$2.20
52-Week Range:
$1.90
$13.93
Xenetic Biosciences Inc Stock (XBIO) Company Profile
Name
Xenetic Biosciences Inc
Sector
Industry
Phone
781-778-7720
Address
945 CONCORD ST., FRAMINGHAM, MA
Compare XBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
2.19 | 5.03M | 2.54M | -4.13M | -4.11M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.91 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.61 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.65 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.52 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.23 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-20 | Initiated | Maxim Group | Buy |
Xenetic Biosciences Inc Stock (XBIO) Latest News
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform - Daily Tribune Media
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting - South Bend Tribune
Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Large Drop in Short Interest - Defense World
Is Xenetic Biosciences Inc. stock affected by interest rate hikesCash Flow Trends & Invest With Confidence - bollywoodhelpline.com
Reviewing Xenetic Biosciences (NASDAQ:XBIO) and Minerva Neurosciences (NASDAQ:NERV) - Defense World
Xenetic Biosciences, Inc. Share Price TodayLive NASDAQ: XBIO Stock Price Charts, History - Upstox
Financial Review: Xenetic Biosciences (NASDAQ:XBIO) & Talphera (NASDAQ:TLPH) - Defense World
Aug Gainers: Will Xenetic Biosciences Inc stock attract more institutional investorsTrend Reversal & High Accuracy Investment Entry Signals - moha.gov.vn
Why Xenetic Biosciences Inc. (3XB0) stock stays on buy listsProduct Launch & High Accuracy Investment Signals - Улправда
Is Xenetic Biosciences Inc. (3XB0) stock dividend growth reliableQuarterly Earnings Summary & Community Verified Swing Trade Signals - Улправда
Bank Watch: Can Xenetic Biosciences Inc. stock sustain institutional interestJuly 2025 Highlights & Weekly Breakout Stock Alerts - Улправда
Will Xenetic Biosciences Inc. stock outperform growth indexesPortfolio Return Report & Reliable Entry Point Alerts - DonanımHaber
Can Xenetic Biosciences Inc. stock sustain institutional interest2025 Earnings Surprises & Daily Stock Momentum Reports - Улправда
Published on: 2025-12-19 04:46:10 - Улправда
Is Xenetic Biosciences Inc. stock gaining market sharePortfolio Risk Report & Low Risk Entry Point Tips - Улправда
Published on: 2025-12-18 17:05:35 - Улправда
Contrasting Cosmos Health (NASDAQ:COSM) and Xenetic Biosciences (NASDAQ:XBIO) - Defense World
Xenetic Biosciences Earnings Notes - Trefis
Value Recap: Will Xenetic Biosciences Inc stock attract more institutional investorsMarket Performance Report & Verified Technical Signals - moha.gov.vn
Xenetic Biosciences adjourns 2025 annual meeting - MSN
Xenetic Biosciences Adjourns 2025 Annual Meeting - TipRanks
Xenetic Biosciences (NASDAQ: XBIO) Resets 2025 Annual Meeting to Jan. 8, 2026 - Stock Titan
Can Xenetic Biosciences Stock Recover If Markets Fall? - Trefis
EBITDA per share of Xenetic Biosciences, Inc. – BER:3XB0 - TradingView
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock - SouthCoastToday.com
Will Xenetic Biosciences Inc. stock keep outperforming rivals2025 Buyback Activity & Risk Controlled Stock Alerts - Newser
Published on: 2025-12-05 14:51:47 - moha.gov.vn
Is Xenetic Biosciences Inc. (3XB0) stock a top hedge fund pick2025 Top Gainers & Reliable Volume Spike Trade Alerts - Newser
Is Xenetic Biosciences Inc. (3XB0) stock a buy for dividend portfoliosWeekly Stock Report & Real-Time Sentiment Analysis - Newser
Xenetic Biosciences, Inc. (XBIO) Jumps 10% in Pre-market: What’s Driving the Move? - Stocks Telegraph
Can Xenetic Biosciences Inc. (3XB0) stock reach $200 price targetJuly 2025 Recap & Weekly Market Pulse Alerts - Newser
Is Xenetic Biosciences Inc. (3XB0) stock a fit for income portfoliosEarnings Beat & Technical Pattern Alert System - Newser
Is Xenetic Biosciences Inc. (3XB0) stock bottoming after sell offWeekly Trade Summary & Weekly Hot Stock Watchlists - Newser
Xenetic Biosciences Inc Stock (XBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.60%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):